Heather M McGee1, Megan E Daly2, Sohelia Azghadi3, Susan L Stewart4, Leslie Oesterich5, Jeffrey Schlom6, Renee Donahue6, Jonathan D Schoenfeld7, Qian Chen8, Shyam Rao3, Ruben C Fragoso3, Richard K Valicenti3, Robert J Canter8, Emmanual M Maverakis8, William J Murphy9, Karen Kelly5, Arta M Monjazeb10. 1. Department of Radiation Oncology, University of California, Davis, Comprehensive Cancer Center, Davis, California; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Department of Radiation Oncology, University of California, Davis, Comprehensive Cancer Center, Davis, California. Electronic address: medaly@ucdavis.edu. 3. Department of Radiation Oncology, University of California, Davis, Comprehensive Cancer Center, Davis, California. 4. Department of Public Health Sciences, University of California, Davis, School of Medicine, Davis, California. 5. Division of Medical Oncology, Department of Medicine, University of California, Davis, Comprehensive Cancer Center, Davis, California. 6. Laboratory of Cancer Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 7. Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts. 8. Laboratory of Cancer Immunology, University of California, Davis, School of Medicine, Davis, California. 9. Laboratory of Cancer Immunology, University of California, Davis, School of Medicine, Davis, California; Department of Dermatology, University of California, Davis, School of Medicine, Davis, California. 10. Department of Radiation Oncology, University of California, Davis, Comprehensive Cancer Center, Davis, California; Laboratory of Cancer Immunology, University of California, Davis, School of Medicine, Davis, California.
Abstract
PURPOSE: Despite the strong interest in combining stereotactic ablative radiation therapy (SAR) with immunotherapy, limited data characterizing the systemic immune response after SAR are available. We hypothesized that the systemic immune response to SAR would differ by irradiated site owing to inherent differences in the microenvironment of various organs. METHODS AND MATERIALS: Patients receiving SAR to any organ underwent prospective blood banking before and 1 to 2 weeks after SAR. Peripheral blood mononuclear cells (PBMCs) and serum were isolated. PBMCs were stained with fluorophore-conjugated antibodies against T and natural killer (NK) cell markers. Cells were interrogated by flow cytometry, and the results were analyzed using FlowJo software. Serum cytokine and chemokine levels were measured using Luminex. We analyzed the changes from before to after therapy using paired t tests or 1-way analysis of variance (ANOVA) with Bonferroni's post-test. RESULTS: A total of 31 patients had evaluable PBMCs for flow cytometry and 37 had evaluable serum samples for Luminex analysis. The total number of NK cells and cytotoxic (CD56dimCD16+) NK cells decreased (P = .02) and T-cell immunoglobulin- and mucin domain-containing molecule-3-positive (TIM3+) NK cells increased (P = .04) after SAR to parenchymal sites (lung and liver) but not to bone or brain. The total memory CD4+ T cells, activated inducible co-stimulator-positive and CD25+CD4+ memory T cells, and activated CD25+CD8+ memory T cells increased after SAR to parenchymal sites but not bone or brain. The circulating levels of tumor necrosis factor-α (P = .04) and multiple chemokines, including RANTES (P = .04), decreased after SAR to parenchymal sites but not bone or brain. CONCLUSIONS: Our data suggest SAR to parenchymal sites induces systemic immune changes, including a decrease in total and cytotoxic NK cells, an increase in TIM3+ NK cells, and an increase in activated memory CD4+ and CD8+ T cells. SAR to nonparenchymal sites did not induce these changes. By comparing the immune response after radiation to different organs, our data suggest SAR induces systemic immunologic changes that are dependent on the irradiated site.
PURPOSE: Despite the strong interest in combining stereotactic ablative radiation therapy (SAR) with immunotherapy, limited data characterizing the systemic immune response after SAR are available. We hypothesized that the systemic immune response to SAR would differ by irradiated site owing to inherent differences in the microenvironment of various organs. METHODS AND MATERIALS: Patients receiving SAR to any organ underwent prospective blood banking before and 1 to 2 weeks after SAR. Peripheral blood mononuclear cells (PBMCs) and serum were isolated. PBMCs were stained with fluorophore-conjugated antibodies against T and natural killer (NK) cell markers. Cells were interrogated by flow cytometry, and the results were analyzed using FlowJo software. Serum cytokine and chemokine levels were measured using Luminex. We analyzed the changes from before to after therapy using paired t tests or 1-way analysis of variance (ANOVA) with Bonferroni's post-test. RESULTS: A total of 31 patients had evaluable PBMCs for flow cytometry and 37 had evaluable serum samples for Luminex analysis. The total number of NK cells and cytotoxic (CD56dimCD16+) NK cells decreased (P = .02) and T-cell immunoglobulin- and mucin domain-containing molecule-3-positive (TIM3+) NK cells increased (P = .04) after SAR to parenchymal sites (lung and liver) but not to bone or brain. The total memory CD4+ T cells, activated inducible co-stimulator-positive and CD25+CD4+ memory T cells, and activated CD25+CD8+ memory T cells increased after SAR to parenchymal sites but not bone or brain. The circulating levels of tumor necrosis factor-α (P = .04) and multiple chemokines, including RANTES (P = .04), decreased after SAR to parenchymal sites but not bone or brain. CONCLUSIONS: Our data suggest SAR to parenchymal sites induces systemic immune changes, including a decrease in total and cytotoxic NK cells, an increase in TIM3+ NK cells, and an increase in activated memory CD4+ and CD8+ T cells. SAR to nonparenchymal sites did not induce these changes. By comparing the immune response after radiation to different organs, our data suggest SAR induces systemic immunologic changes that are dependent on the irradiated site.
Authors: Encouse B Golden; Sandra Demaria; Peter B Schiff; Abraham Chachoua; Silvia C Formenti Journal: Cancer Immunol Res Date: 2013-12 Impact factor: 11.151
Authors: Ines Pires da Silva; Anne Gallois; Sonia Jimenez-Baranda; Shaukat Khan; Ana C Anderson; Vijay K Kuchroo; Iman Osman; Nina Bhardwaj Journal: Cancer Immunol Res Date: 2014-02-11 Impact factor: 11.151
Authors: Simón Méndez-Ferrer; Tatyana V Michurina; Francesca Ferraro; Amin R Mazloom; Ben D Macarthur; Sergio A Lira; David T Scadden; Avi Ma'ayan; Grigori N Enikolopov; Paul S Frenette Journal: Nature Date: 2010-08-12 Impact factor: 49.962
Authors: Derek Ng Tang; Yu Shen; Jingjing Sun; Sijin Wen; Jedd D Wolchok; Jianda Yuan; James P Allison; Padmanee Sharma Journal: Cancer Immunol Res Date: 2013-07-31 Impact factor: 11.151
Authors: M Zahidunnabi Dewan; Ashley E Galloway; Noriko Kawashima; J Keith Dewyngaert; James S Babb; Silvia C Formenti; Sandra Demaria Journal: Clin Cancer Res Date: 2009-08-25 Impact factor: 12.531
Authors: Alison Crawford; Jill Marie Angelosanto; Kim Lynn Nadwodny; Shawn D Blackburn; E John Wherry Journal: PLoS Pathog Date: 2011-07-21 Impact factor: 6.823
Authors: Arta M Monjazeb; Kurt A Schalper; Franz Villarroel-Espindola; Anthony Nguyen; Stephen L Shiao; Kristina Young Journal: Semin Radiat Oncol Date: 2020-04 Impact factor: 5.934
Authors: Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal Journal: Front Oncol Date: 2021-04-21 Impact factor: 6.244
Authors: Jeongshim Lee; Jee Suk Chang; Mi Ryung Roh; Minkyu Jung; Choong-Kun Lee; Byung Ho Oh; Kee Yang Chung; Woong Sub Koom; Sang Joon Shin Journal: Cancer Res Treat Date: 2020-02-13 Impact factor: 4.679
Authors: Umair Mahmood; Andrew Bang; Yu-Hui Chen; Raymond H Mak; Jochen H Lorch; Glenn J Hanna; Mizuki Nishino; Claire Manuszak; Emily M Thrash; Mariano Severgnini; Matthew Sanborn; Vishwajith Sridharan; Danielle N Margalit; Roy B Tishler; Paul M Busse; Henning Willers; Harvey J Mamon; Hyung-Jin Yoo; Sara I Pai; Lori J Wirth; Robert I Haddad; Nicole G Chau; Jonathan D Schoenfeld Journal: Int J Radiat Oncol Biol Phys Date: 2020-08-08 Impact factor: 8.013
Authors: Matthew C Knox; Jie Ni; Andrej Bece; Joseph Bucci; Yaw Chin; Peter H Graham; Yong Li Journal: Front Immunol Date: 2020-07-22 Impact factor: 7.561
Authors: Eric J Lehrer; Heather M McGee; Jennifer L Peterson; Laura Vallow; Henry Ruiz-Garcia; Nicholas G Zaorsky; Sonam Sharma; Daniel M Trifiletti Journal: Int J Mol Sci Date: 2018-10-07 Impact factor: 5.923